Avenue Therapeutics, Inc. Stock News

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the Company) (NASDAQ: ATXI), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share. Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the Company.

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COV

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such invest

NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors ar

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors ar

The stock price of Avenue Therapeutics, Inc. (Nasdaq: ATXI) fell by over 15% pre-market. This is why it happened.

The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA

The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) increased by over 15% pre-market. This is why it happened.

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced th

One of the company's subsidiaries announced some good news today.

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) 10X Genomics Inc (NASDAQ: TXG) ALX Oncology Holdings Inc (NASDAQ: ALXO) Avenue Therapeutics Inc (NASDAQ: ATXI)...

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) DarioHealth Corp (NASDAQ:...

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.